NTRK1 and cancer: Oncogenic mutations in cancer can lead to decreased receptor tyrosine kinases ubiquitination, either due to mutations of the binding sites for ubiquitin ligases in the receptors themselves, or through inactivating mutations in the ubiquitin ligases [10].